Research progress on radiotherapy technology and dose fraction scheme for advanced gliomas

1Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Glioma is the most common central malignant tumor. High-grade glioma (HGG) has high malignancy and a short median survival. Complete surgical resection and comprehensive treatment with postoperative radiotherapy and chemotherapy is the recommended treatment for HGGs at present in clinic. Postoperative radiotherapy can reduce the local recurrence rate and prolong the survival time of patients. In recent years, researchers have made some progress on different radiotherapy technologies and dose fraction schemes. With the continuous development of medical technology, different groups of people should choose different dose fraction schemes, in order to realize the individualization of treatment schemes, and provide more benefits to patients. At present, the optimal radiotherapy dose, the fraction model, and how to achieve individualized radiotherapy remains unclear. In view of the poor prognosis of this disease, patients should be encouraged to participate in properly conducted experimental studies.

Cite

CITATION STYLE

APA

Zhang, Y., & Wang, J. (2020, December 1). Research progress on radiotherapy technology and dose fraction scheme for advanced gliomas. Translational Cancer Research. AME Publishing Company. https://doi.org/10.21037/tcr-20-1891

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free